Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier
P
P
Prebet
T
T
Pigneux
A
A
Hunault
M
M
Delaunay
J
J
Perry
F
F
Lode
L
L
Richebourg
S
S
Blanchet
O
O
Vey
N
N
Ifrah
N
N
Milpied
N
N
Blaise
D
D
Harousseau
J-L
JL
Mohty
M
M
D000328:Adult; D000368:Aged; D000617:Aminoglycosides / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics; D009687:Nuclear Proteins / Q000235:genetics*; D000090243:Nucleophosmin; D011379:Prognosis; D016879:Salvage Therapy; D020080:Tandem Repeat Sequences; D016896:Treatment Outcome; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C000716967:NPM1 protein, human; D009687:Nuclear Proteins; D000090243:Nucleophosmin; D000079982:Gemtuzumab; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3